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Abstract
BACKGROUND—In 2012, over 240,000 men were diagnosed with prostate cancer and over 
28,000 died from the disease. Animal models of prostate cancer are vital to understanding its 
pathogenesis and developing therapeutics. Canine models in particular are useful due to their 
similarities to late-stage, castration-resistant human disease with osteoblastic bone metastases. 
This study established and characterized a novel canine prostate cancer cell line that will 
contribute to the understanding of prostate cancer pathogenesis.
METHODS—A novel cell line (Probasco) was derived from a mixed breed dog that had 
spontaneous prostate cancer. Cell proliferation and motility were analyzed in vitro. Tumor growth 
in vivo was studied by subcutaneous, intratibial, and intracardiac injection of Probasco cells into 
nude mice. Tumors were evaluated by bioluminescent imaging, Faxitron radiography, µCT, and 
histology. RT-PCR and genome-wide DNA copy number profiling were used to characterize the 
cell line.
RESULTS—The Probasco cells grew in vitro (over 75 passages) and were tumorigenic in nude 
mice. Probasco cells expressed high levels of BMP2, CDH1, MYOF, FOLH1, RUNX2, and 
SMAD5 modest CXCL12, SLUG, and BMP, and no PTHrP mRNA. Following intracardiac 
injection, Probasco cells metastasized primarily to the appendicular skeleton, and both intratibial 
and intracardiac injections produced osteoblastic tumors in bone. Comparative genomic 
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hybridization demonstrated numerous DNA copy number aberrations throughout the genome, 
including large losses and gains in multiple chromosomes.
CONCLUSIONS—The Probasco prostate cancer cell line will be a valuable model to investigate 
the mechanisms of prostate cancer pathogenesis and osteoblastic bone metastases.
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INTRODUCTION
The American Cancer Society estimates that approximately 1,660,290 Americans will be 
diagnosed with cancer in 2013. Approximately 238,590 of those cases will be prostate 
cancer [1]. Prostate cancer affects 1 in 6 men in the western world, and 17% of affected men 
will die as a direct result of metastatic disease [2]. The most common site of metastasis is 
bone, and approximately 90% of patients with metastatic disease will develop bone 
metastases that are predominantly osteoblastic or bone-forming [3,4]. Even though the 
pathogenesis of prostate cancer has been studied for over 70 years, few experimental models 
of osteoblastic skeletal metastasis have been developed [5]. Animal models of prostate 
cancer that mimic disease in men are vital for translational research and developing new 
diagnostics and therapeutics to improve patient quality of life.
To understand the pathogenesis of prostate cancer, animal models must reflect one or more 
stages of the human disease. This includes slow growth, increased incidence with age, 
prostatic intraepithelial neoplasia (PIN), initial androgen sensitivity followed by castration 
resistance, and development of predominantly osteoblastic bone metastases in late-stage 
disease. At this time, there is no animal model that encompasses all of these features; 
however, dogs are the best available model for spontaneous disease. Aside from humans, 
dogs are the only animal to naturally develop prostate cancer; however, the incidence is 
lower than in men [6]. As with men, dogs develop prostate cancer late in life [7]. By the 
time prostate cancer is diagnosed in dogs, as many as 80% will have metastases and, similar 
to men, the metastases are often in bone and are typically osteoblastic [8]. For this reason, 
canine prostate cancer is a relevant model of late-stage human disease.
An important difference to note between men and dogs is the role of androgens in prostate 
cancer pathogenesis. The androgen signaling pathway is considered essential to the 
development of prostate cancer in men [9]. In men the androgen signaling pathway is the 
therapeutic target in both early and late-stage disease, even after progression to androgen-
resistance [10]. In dogs the androgen receptor (AR) is present in normal prostatic tissue and 
is necessary for the development of BPH in adult intact male dogs. However, most dogs 
with prostate cancer lack expression of the AR [11]. It is possible that androgen signaling 
does not play a central role in the pathogenesis of canine prostate cancer as it does in men. 
Interestingly, while the secretory cells of the prostate are androgen dependent, the prostatic 
ducts and urothelium of the prostatic urethra are maintained independent of androgen 
signaling [12]. This suggests that canine prostate cancer may originate from prostatic 
ductular epithelium rather than the acinar secretory cells as in men.
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There are few canine prostate cancer cell lines used in research [13–17]. We report the 
formation and characterization of a novel canine prostate adenocarcinoma cell line 
originating spontaneously from a mixed-breed dog. The Probasco cells have unique 
morphologic features that include robust growth in vitro, slow but consistent growth in vivo 
and dramatic osteoblastic bone metastases in nude mice. These characteristics make the 
Probasco cells a valuable resource in prostate cancer research.
MATERIALS AND METHODS
Establishment of Canine Prostate Carcinoma Cell Line (Probasco)
A section of tissue was aseptically removed from a primary prostate carcinoma of a 10.5-
year-old castrated mixed-breed dog that had been previously treated with palliative radiation 
therapy and metronomic chemotherapy (piroxicam, cyclophosphamide, toceranib phosphate, 
and chlorambucil). The clinical disease was approximately 9 months, and at the time of 
tumor sampling there was a suspected right hind limb metastasis that was not confirmed due 
to elective euthanasia. The owner declined a post-mortem examination. The tumor specimen 
was rinsed three times with sterile Dulbecco’s phosphate-buffered saline (DPBS) and 
minced to approximately 1 mm3 fragments with scalpels. The minced tumor was then 
cultured in DMEM/F12 with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
in a 25 cm2 flask. Medium was replaced every 4 days. Differential trypsinization with 0.25% 
trypsin ethylenediamine-tetraacetic acid (EDTA) was used to remove stromal cells, which 
released from the culture flasks earlier than the epithelial cells. Detachment of the cells was 
monitored every 2 min to remove the stromal cells. Once this population was removed, the 
remaining epithelial cells were collected and replated. The epithelial cells were allowed to 
become 70% confluent before passaging.
Lentiviral Luciferase Transduction
The Probasco cells were grown in a 6-well culture plate with DMEM/F12, 10% FBS and 1% 
penicillin/streptomycin. Once the cells had reached approximately 95% confluence, the 
media was removed and replaced with 500µl of luciferase-containing virus (VC 2192 
ConcpLuc (VSV-G)), 1.5 ml of culture medium, and 1.6µl of polybrene stock (8 µg/ml). 
YFP-Luc lentiviral particles were produced by transient co-transfection of 293T cells with 
10 µg packaging plasmid pCMVΔR8.2. 2µg envelope plasmid pMD.G (obtained from Dr. 
Kathleen Boris-Lawrie, Ohio State Univ.) and 10 µg transfer plasmid pHIVSIN-YFP-Luc 
using calcium phosphate (Sigma–Aldrich, St. Louis, MO) as previously described [18]. 
Following centrifugation at 2,700 rpm for 60 min at 30°C, the plate was placed in a cell 
culture incubator at 37°C and 5% CO2 for 24 hr, after which the virus-containing media was 
aspirated and replaced with fresh culture media without virus. After 48 hr the cells were 
detached with trypsin and grown in 25 cm2 flasks as described above.
Subcutaneous, Intratibial, and Intracardiac Injection of Probasco Cells Into Nude Mice
All animal experimental procedures were approved by The Ohio State University 
Institutional Laboratory Animal Care and Use Committee.
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Subcutaneous—Five nude mice were anesthetized in an induction chamber with 3% 
isoflurane. The dorsal thoracic skin was scrubbed with alcohol-soaked gauze to remove 
superficial contamination. A suspension of 500,000 luciferase/YFP-transduced Probasco 
cells (Probasco-Luc) in 0.25 ml of sterile DPBS was injected subcutaneously between the 
shoulder blades using a 25-ga needle. Tumor volume was measured weekly using calipers. 
Measurements were taken in three dimensions and tumor volume was calculated using the 
formula length × width × height × 1/2. Tumor growth was also monitored weekly using 
bioluminescent imaging.
Intratibial—Fifteen nude mice were anesthetized in an induction chamber with 3% 
isoflurane and maintained with 2.5% isoflurane. The right rear limb was scrubbed with 
alcohol-soaked gauze. The leg was held so the knee joint was at a 90° angle and a 27-ga 
needle was introduced through the patellar ligament and into the tibial marrow space 
through the articular cartilage. Using a Hamilton syringe, 0.025 ml of sterile DPBS 
containing a suspension of 200,000 Probasco-Luc cells was introduced into the marrow 
cavity. Tumor growth was monitored weekly using bioluminescent imaging.
Intracardiac—Eight nude mice were induced at 3% isoflurane gas anesthesia and 
maintained at 2.5%. The mice were placed in dorsal recumbency and their front limbs were 
placed perpendicular to their thorax and restrained to the procedure table with surgical tape. 
The ventral thorax was scrubbed with alcohol. A 1 ml syringe with a 25-ga needle was 
loaded with 0.1 ml of DPBS containing a suspension of 300,000 and was introduced into the 
thoracic cavity through the third intercostal space, approximately 1 mm to the left and lateral 
from the sternum. Once a pulsatile jet of blood was present in the hub of the needle, the cell 
suspension was slowly injected into the left ventricle of the heart for 30 sec. Tumor growth 
was monitored weekly using bioluminescent imaging.
Bioluminescent Imaging
Mice were anesthetized in an induction chamber with 3% isoflurane and maintained with 
2% isoflurane. A 1 ml syringe was used to inject 0.15 ml of sterile DPBS containing 4.5 mg 
D-Luciferin (Caliper Life Sciences, Hopkinton, MA) into the peritoneal cavity. 
Bioluminescent in vivo imaging was performed using the IVIS 100 (Caliper Life Sciences) 
and photon signal intensity was quantified using LivingImage software version 2.50 (Caliper 
Life Sciences). Imaging was performed every 2 min until peak photon signal was achieved 
(approximately 10 min post-injection). The IVIS 100 was set to 1 min exposures with small 
binning.
In Vitro Growth Rate
Probasco-Luc cells from passage 25 were plated in a six-well cell culture plate in triplicate 
at a density of 200,000 cells per well. Cells were cultured in DMEM/F12 with 10% FBS and 
1% penicillin/streptomycin and incubated in 37°C and 5% CO2. The cells were collected 
using 0.25% trypsin at 24, 48, and 72 hr after the initial plating and counted with an 
automated cell counter (Nexcelom Bioscience, Lawrence, MA) using trypan-blue dye 
exclusion to differentiate between live and dead cells. The doubling time was calculated 
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using the formula: (t2 − t1) × log(n2)/log(n2/n1), where n is the cell number at time points 
(t).
Histopathology and Immunohistochemistry
Complete necropsies were performed on the mice, subcutaneous tumors were weighed, and 
tissues were fixed in 10% neutral-buffered formalin at 4°C for 24 hr. Bones were decalcified 
in 10% EDTA (pH 7.4) for 2 weeks at 4°C and embedded in paraffin. The specimens were 
sectioned (5µm) and were either stained with hematoxylin and eosin (H&E) or evaluated by 
immunohistochemistry against cytokeratins AE1/AE3, 5/6, 7, and 20 (Table I).
RNA Extraction and Quantitative Real-Time Reverse Transcription-Polymerase Chain 
Reaction (qRT-PCR)
Total RNA was extracted from Probasco cells at passages 4, 5, and 6 and Ace-1 canine 
prostate carcinoma cells at passages 22, 23, and 24 using the Absolutely RNA Miniprep Kit 
(Stratagene, Cat. No. 400800) and the manufacturer’s protocol for adherent tissue culture 
cells. Total RNA (0.5 µg) was reverse transcribed using the Superscript II First Strand 
cDNA synthesis kit (Invitrogen, Carlsbad, CA) and RT-PCR was performed for the 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as well as the 
following genes related to bone microenvironment and prostate cancer progression and 
metastasis: bone morphogenic protein-2 (BMP2), cadherin-1 (CDH1), chemokine ligand 12 
(CXCL12), folate hydrolase 1 (FOLH1), myoferlin (MYOF), runt-related transcription 
factor 2 (RUNX2), snail homolog 2 (SLUG), parathyroid hormone-related peptide (PTHrP), 
AR, and mothers against decapentaplegic homolog 5 (SMAD5) using canine specific 
primers (Table II). Each primer pair was chosen from three to four different primer pairs 
designed for each gene. These primers were compared side-by-side and the primer pair that 
had the best amplification and qRT-PCR product melting characteristics was chosen for 
each gene. All primer pairs were designed using Primer-BLAST software (http://
www.ncbi.nlm.nih.gov/tools/primer-blast). In order to confirm primer specificity, qRT-PCR 
products for each gene were verified by electrophoresis on a 2% agarose gel and stained 
with ethidium bromide to confirm a single amplification product of the expected size. The 
entire PCR reactions were then purified using the QIAquick PCR Purification Kit (Qiagen, 
cat. No. 28106) and sequenced by the Plant-Microbe Genomics Facility at The Ohio State 
University using a 3730 DNA Analyzer (Applied Biosystems, Grand Island, NY) and 
BigDye Terminator Cycle Sequencing chemistry (Applied Biosystems). Sequences were 
verified by a BLAST search using the NCBI website.
DNA Extraction and Polymerase Chain Reaction (PCR)
Total DNA was extracted from Probasco cells at passage 6 using the DNeasy Blood & 
Tissue Kit (Qiagen, Cat. No. 69581) and the manufacturer’s protocol for adherent tissue 
culture cells. PCR was performed for the AR using canine specific primers (Table II).
Radiography
Radiography was performed postmortem on the mice that received intratibial and 
intracardiac injections. Formalin-fixed tissues were placed centrally on a Faxitron laboratory 
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radiography system LX-60 (Faxitron X-ray Corp., Wheeling, IL) imaging platform and 
high-resolution radiographs were taken at 25KV and 5 sec exposures.
Micro-Computed Tomography (µCT)
The tibias were removed postmortem from mice injected intratibially and imaged using 
microcomputed tomography (µCT) (Siemens, Inveon Preclinical CT scanner, Siemens AG, 
Munich, Germany). Images were acquired in 400 projections over 360° at 100 kVp, 200 
MA, 900 ms exposure, Bin 2, and a medium-high system magnification with a pixel width 
of 19 µm. Image data were reconstructed using Cobra software (Exxim, Pleasanton, CA) and 
analyzed using 3D analysis software (Inveon Research Workplace 3-Dimensional Image 
Software, Siemens PreClinical). Segmentation thresholds were kept constant for all bones. 
Five mice were euthanized at 3 weeks post-injection to characterize early lesions and other 
mice were euthanized at 6 weeks (late lesions).
Analysis of Genomic Imbalances by Comparative Genomic Hybridization (CGH) and 
Fluorescence In Situ Hybridization (FISH)
Metaphase chromosome preparations and genomic DNA were obtained simultaneously from 
the same flask of cells. The cells in the flask were grown to 80% confluence and exposed to 
50 ng/ml of Karyomax (Invitrogen) for 4 hr prior to routine recovery from the flask with 
conventional trypsin-EDTA. Pelleted cells were divided equally into two tubes, one used to 
isolate genomic DNA for array comparative genomic hybridization (aCGH) and the second 
harvested for chromosome preparations by routine procedures [19,20].
Chromosome preparations were isolated following conventional procedures of hypotonic 
treatment and fixation in 3:1 methanol:glacial acetic acid. To identify the position of the 
centromeres of the chromosomes, two BAC clones (330E21 and 326K03) from the 
CHORI-82 BAC library, which have been shown previously to hybridize to all autosomal 
centromeres of the canine genome, were both labeled with SpectrumGreen-dUTP and 
hybridized to chromosome preparations of this cell line according to routine procedures 
[21]. Chromosome preparations were counterstained with 80ng/ml 4′,6-diaminidino-2-
phenylindole (DAPI) and mounted in antifade solution (Vectashield, Vector Laboratories, 
Burlingame, CA). Images were acquired with a fluorescence microscope (Axioplan 2ie, 
Zeiss) equipped with a DAPI filter set and a cooled CCD camera (CoolSnapHQ, 
Photometrics, Tuscon, AZ) both driven by dedicated software (SmartCapture 3, Digital 
Scientific, Cambridge, UK).
CGH was performed using a commercial ~180,000-feature microarray comprising repeat-
masked ~60-mer oligonucleotides distributed at approximately 13 kb intervals throughout 
the dog genome sequence assembly (canFam version 2.0, May 2005 [22]) (Agilent 
Technologies, Santa Clara, CA). All steps were performed as described previously [20]. 
Briefly, DNA isolated from the cell line was labeled with cyanine-3-dUTP and hybridized 
against a reference DNA sample (comprising equimolar quantities of constitutional DNA 
from 10 clinically healthy male dogs) labeled with Cyanine-5-dUTP. Following 
hybridization and washes the array image file was processed using Feature Extraction 
version 10.10 (Agilent Technologies) and imported into Nexus Copy Number version 7 
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(BioDiscovery, El Segundo, CA). DNA copy number calling was performed using the 
FASST2 segmentation algorithm in Nexus Copy Number, using at least three consecutive 
probes with log2 tumor: reference values of ≥0.201 or ≤−0.234 to indicate copy number gain 
or loss. Genomic recoding of the canine genome coordinates to represent the corresponding 
human genome locations was performed as described previously [20]. The resulting 
‘humanized’ data were output simultaneously to facilitate direct comparison with CGH data 
already available for human prostate specimens.
Statistical Analysis
Results are displayed as means ± SD. Normalized gene expression data were analyzed using 
one-way ANOVA followed by Sidak’s multiple comparisons test to perform comparisons 
using GraphPad Prism version 6.03 (La Jolla, CA). Data with P values <0.05 were 
considered statistically significant.
RESULTS
Histopathologic Characterization of the Primary Carcinoma and Subcutaneous Xenograft
The primary prostate carcinoma was a moderately differentiated alveolar-type prostatic 
carcinoma based on the light microscopic morphology. The carcinoma was composed of 
numerous ducts filled with polygonal epithelial cells arranged in nests and anastomosing 
cords (Fig. 1A). The cancer cells contained moderate homogenous eosinophilic cytoplasm 
and a single, round to oval nucleus with finely stippled chromatin and 1–2 nucleoli. 
Desmoplasia was present throughout the tumor, as well as multifocal areas of necrosis and 
lymphocytic inflammation.
Probasco xenografts were grossly visible in the subcutis of all mice between 2 and 4 weeks 
after implantation. Mice were euthanized 7 weeks after implantation, and tumors ranged in 
size from 170 to 430 mm3. The histologic appearance of the xenograft was similar to the 
primary carcinoma and was comprised of polygonal epithelial cells forming nests and 
anastomosing cords in a fine fibrovascular stroma with moderate to severe multifocal 
coagulation necrosis (Fig. 1B). Pseudo-cyst formation was common in the tumor secondary 
to necrosis, and the neoplastic cells lined cavities containing sloughed cells. Occasionally, 
small foci of mineralization and ectopic bone formation were present. Subcutaneous tumors 
were not highly invasive and were easily dissectible from the subcutaneous space.
Immunohistochemistry
The Probasco cells were positive for pan-cytokeratins AE1/AE3 and 5/6 and negative for 
cytokeratins 7 and 20 (data not shown).
In Vitro and In Vivo Growth
The Probasco cells grew in an anchorage-dependent manner in vitro and formed monolayer 
sheets with polygonal cells exhibiting a tightly packed cobblestone growth pattern (Fig. 1C). 
Probasco cells grew exponentially in vitro with a doubling time of approximately 18 hr 
under standard culture conditions (Fig. 2A). In vivo, the doubling time of the viable cells in 
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subcutaneous xenografts was approximately 2.5 weeks as estimated by BLI (Fig. 2B). The 
subcutaneous xenograft volume doubled approximately every 1.4 weeks (Fig. 2C).
qRT-PCR and PCR of Probasco In Vitro
The Probasco cells expressed a high level of CDH1, MYOF, FOLH1, SMAD5, and RUNX2 
and a modest level of BMP2, SLUG, and CXCL12 (Fig. 3A and B). There was little to no 
expression of PTHrP. Probasco cells expressed significantly greater BMP2, CDH1, MYOF, 
RUNX2, FOLH1, and SMAD5 mRNA compared to a second canine prostate carcinoma cell 
line, Ace-1 (Fig. 3B). The expression of CXCL12, PTHrP and SLUG were significantly 
lower in Probasco cells. Neither cell line expressed AR mRNA, though the gene was present 
by PCR.
Intratibial Injections of Probasco in Nude Mice
Fourteen of 15 mice developed successful xenografts in the tibias. Radiographs and µCT 
imaging demonstrated extensive new bone formation on both the endosteal and periosteal 
surfaces of the tibias (Fig. 4A and B). The new bone formed a radio-opaque starburst pattern 
of woven bone emanating from the periosteal surface, while the endosteal new bone 
presented as sclerosis of the marrow cavity with loss of distinct trabeculae. In the early 
lesions (3 weeks post-injection), the new woven bone was confined to the endosteal surfaces 
and marrow spaces. At 6 weeks post-injection the Probasco cells penetrated the cortical 
bone and induced marked periosteal new bone formation. The overall effect on the bone was 
markedly osteoblastic, with mild osteolysis. Histology of the tibia demonstrated large 
multifocal to coalescing islands of woven bone lined by both numerous cuboidal osteoblasts 
and polygonal neoplastic cells (Fig. 5). Large intratibial tumors formed pseudocystic cavities 
that contained necrotic cell and proteinaceous (eosinophilic) fluid.
Intracardiac Injections (IC) and In Vivo Bioluminescent Imaging (BLI) of Probasco in Nude 
Mice
Six of eight mice developed bone metastases (ranging from 1 to 5 metastases per mouse) 
after IC injection with Probasco cells. At 5 min after injection of Probasco cells and IP 
luciferin administration, the bioluminescence was diffusely distributed throughout the body, 
with the highest signal within the thoracic cavity. Two mice had bioluminescence within the 
forelimbs at day seven. By 2 weeks, six of the eight mice had bioluminescence within in the 
appendicular skeleton. The intensity of the BLI increased throughout weeks 3 and 4, 
reflecting increased tumor burden. At the end of week 4, bioluminescence demonstrated 
metastases in the femurs of two mice, tibias in six mice, radius/ulnar metastases in five 
mice, and vertebrae in four mice. One mouse with vertebral tumor growth had bilateral hind 
limb paralysis at the time of euthanasia. Faxitron radiography demonstrated numerous radio-
opaque radial spicules of periosteal new bone formation and medullary sclerosis in both the 
metaphysis and diaphysis of long bones, with minimal osteolysis.
Analysis of Genomic Imbalances by CGH and FISH
Analysis of >50 DAPI stained metaphase preparations indicated that while the cell line was 
not clonal, all of the cells evaluated were hyperdiploid, containing between 88 and 108 
Simmons et al. Page 8
Prostate. Author manuscript; available in PMC 2014 November 02.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
chromosomes, with a mean of 92. Hybridization of BAC clones targeting the centromeres of 
all canine autosomes [23] revealed that while most of the chromosomes were single-armed, 
approximately 20% were bi-armed, indicative of centric fusions (Fig. 6). Centromeres were 
not detected on either of two grossly different bi-armed chromosomes, suggesting that these 
two aberrant structures may contain centromeres from the sex chromosomes, even though 
neither resembled a “normal” canine X or Y chromosome.
The genome wide profile of DNA isolated from passage four of the Probasco line revealed 
numerous copy number aberrations, representing whole (or almost whole) chromosomes 
(e.g., gain of dog chromosome (CFA) 4, 11, 20, 24, and 26 and loss of CFA 7, 19, 27, 33, 
34, and 36), large chromosome segments (e.g., gain of large regions of CFA 9, 13, 14, 18 
and loss of regions of CFA 1, 3, 12, 13, 16, 22, 31, and Xq) (Fig. 7). In addition there were 
numerous focal copy number changes involving gains of small regions of CFA 2, 13, 20, 34, 
and 36, and losses of small regions of CFA 8 and 28 (Fig. 7). The complex pattern of 
adjacent DNA copy number gain and loss along CFA 13 and Xq is suggestive that these 
chromosomes may be involved in complex translocation events, which would merit further 
investigation. Recoding of the canine data to output the profile in the context of the human 
genome is presented in Figure 8.
DISCUSSION
The creation of cell lines and animal models that closely recapitulate prostate cancer 
progression in men is essential for understanding prostate cancer pathogenesis and the 
development of novel therapeutics [24,25]. Dog are unique in the animal kingdom because 
they develop spontaneous prostate cancer with an increasing incidence with age and 
frequently develop osteoblastic bone metastases [8]. In this study, we describe the 
development and characterization of a novel canine prostate cancer cell line (Probasco).
There are six canine prostate cancer cell lines that have been reported (DPC-1, CPA-1, 
Ace-1, Leo, CT-1258, and Probasco), each with unique characteristics that contribute to 
prostate cancer research. The Leo cell line produces osteolytic bone metastases and, more 
importantly, consistently metastasizes to the brain and spinal cord after intracardiac injection 
[13]. The Ace-1 cell line demonstrates marked epithelial-mesenchymal transition and 
produces mixed osteoblastic and osteolytic metastases [14]. The Ace-1 cells have been used 
to develop an experimental model of prostate cancer in immunosuppressed dogs to 
investigate molecular imaging, focal therapy of prostate cancer, and metastasis to lymph 
nodes, lungs and bone [7,26]. The DPC-1 cell line is tumorigenic in both mice and dogs and 
produces undifferentiated prostate carcinoma xenografts [16,27]. In immunosuppressed 
dogs, DPC-1 metastasizes to lung, lymph node, and produced mixed osteoblastic and 
osteolytic bone metastases [27]. The CPA-1 cell line, while not extensively characterized, is 
tumorigenic in nude mice and produces well differentiated prostate carcinoma xenografts 
[17]. The CT-1258 cell line produces tumors when injected subcutaneously or 
intraperitoneally in immunodeficient mice and does not metastasize [15]. Of all the canine 
prostate cancer cell lines, the Probasco cell line is the only one to produce predominantly 
osteoblastic bone metastases. As men with prostate cancer bone metastases most commonly 
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develop osteoblastic lesions, so the Probasco cells represent a uniquely valuable tool for 
evaluating this particular aspect of prostate cancer pathogenesis.
There are few animal models of prostate cancer bone metastasis that closely mimic human 
disease. Most currently available genetically modified mouse models of prostate cancer do 
not develop bone metastases, and xenograft models of prostate cancer bone metastasis often 
result in the formation of mixed or osteolytic metastases [28]. The two most commonly used 
human lines that stimulate new bone formation include the human LNCap subline C4-2B 
and the LuCaP 23.1 tumor line; however, both of these form mixed metastases as they 
induce significant bone destruction as well as formation [29,30]. A less commonly used 
human cell line, the MDA PCA 2b cells, forms predominantly osteoblastic lesions when 
injected into mouse long bones, however, it takes significantly longer (60 days) than the 
Probasco cells (21 days) for osseous lesions to become evident [31]. It is expected that 
ability of the Probasco cells to mimic the osteoblastic nature of human prostate cancer bone 
metastases will further the understanding of the pathogenesis of osteoblastic metastases in 
prostate cancer, creating the potential for novel therapeutics, and imaging modalities.
The pathogenesis of bone metastases has been intensely investigated over the last decade, 
but there is still much to understand. Cell lines that actively metastasize and grow in bone 
are vital to advancing our understanding of this untreatable disease. Comparing cell lines 
that produce osteoblastic metastases to cell lines that produce mixed or osteolytic lesions 
may help identify important pathways in the molecular pathogenesis of osteoblastic prostate 
cancer bone metastases. As previously mentioned, the Ace-1 canine prostate cancer cell line 
(developed by our lab) metastasizes to bone and forms mixed osteoblastic/osteolytic lesions 
[14]. This is in contrast to the osteoblastic lesions induced by the Probasco cells. When 
comparing gene expression between these two cell lines, several genes were identified that 
may provide insight into the reasons for their different metastatic phenotypes. One such 
gene is BMP2. Interestingly, Probasco has a much higher expression of BMP2 compared to 
Ace-1. Bone morphogenic proteins are growth factors of the transforming growth factor-
beta (TGF-β) superfamily that transduce signals through SMADs and have a critical role in 
bone formation [32]. BMP signaling activates SMAD1/5/8, resulting in upregulation of 
transcription factor and coactivators that are important in osteoblast differentiation (i.e., 
Osterix and RUNX2) and new bone formation [33,34]. The elevated expression of BMP2 
may play a role in the osteoblastic nature of Probasco bone metastases. Another gene is 
CXCL12, a chemokine ligand that regulates proteases such as MMP9. The decreased 
expression of CXCL12 in the Probasco cells may in part account for the reduced osteolysis 
in bone metastases compared to the Ace-1 cells [35].
Osteomimicry has been implemented as an important feature in bone metastasis for over a 
decade, and has been found to be a feature of prostate cancer bone metastasis in men [36]. 
The theory of osteomimicry proposes that neoplastic cells express bone matrix proteins or 
osteoblast-related factors to enhance their survival and proliferation in bone. One such factor 
is the osteoblast transcription factor, RUNX2 [37]. RUNX2 targets pathways such as Wnt, 
Src, BMP, and TGF-β and is considered a key regulator of metastasis-related genes in 
human prostate cancer [34]. Elevated RUNX2 expression has been documented in advanced 
human prostate cancer compared to early lesions [38]. The elevated expression of RUNX2 
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in the Probasco cells supports its use as a model of late-stage human prostate cancer and 
potentially provides a model to target osteomimicry in the development of therapeutics.
Both Probasco and Ace-1 have similar levels of expression of FOLH1. This gene, also 
known as prostate-specific membrane antigen, has been under intense investigation in recent 
years for its use as a target for prostate cancer imaging by positron emission tomography 
(PET), single photon emission computed tomography (SPECT), and transrectal gamma 
imaging (TRGI) [39–42]. FOLH1 is overexpressed in most human prostate cancers, and a 
similar overexpression in canine prostatic carcinoma cell lines makes them a useful tool in 
validating such imaging studies.
The role of parathyroid hormone-related peptide in prostate cancer is not clearly defined. In 
other tumors, such as breast and lung cancer, PTHrP plays significant role osteolytic 
metastases. In these tumors, PTHrP is thought to be one of the main drivers of the “vicious 
cycle” from its ability to enhance osteoclastogenesis and bone lyses [43]. The function of 
PTHrP in prostate cancer is less clear, though the predominantly osteoblastic nature of 
metastases suggests it plays a different role in the progression of bone metastases. One study 
has found that PTHrP overexpression in the Ace-1 cell line is linked to increased 
osteoblastogenesis, osteoclastogenesis, and angiogenesis as well as increased bone turnover 
[44]. Interestingly, reports of PTHrP expression in prostate cancer bone metastases are 
conflicting, with several reports claiming its presence in 100% of human prostate cancer 
bone metastases and others reporting a less universal expression [45,46]. The Probasco cell 
line may be useful as a model of bone metastases that have little to no expression of PTHrP, 
perhaps highlighting the importance of other pathways in disease progression.
Epithelial-mesenchymal transition (EMT) is a well-known characteristic of invasive tumors. 
EMT is often characterized by loss of expression of cell–cell adhesion molecules like E-
cadherin and increased expression of mesenchymal proteins, such as vimentin [47]. The 
relatively high expression of CDH1 in Probasco cells compared to Ace-1 suggests that it has 
not undergone extensive EMT. This is supported by its polygonal cell shape both in culture 
and in vivo. The lack of prominent EMT may explain why the subcutaneous Probasco 
xenografts are minimally invasive and easy to dissect from the mouse when compared to 
Ace-1 xenografts, which are reported to invade into the underlying epaxial musculature, ribs 
and vertebrae [14]. Interestingly, the Probasco cells express higher levels of myoferlin 
(MYOF) compared to Ace-1. MYOF has not been investigated in prostate cancer, however, 
several studies have indicated a role in breast cancer. Knockdown of MYOF in breast cancer 
cells resulted in reduced invasion and mesenchymal to epithelial transition (MET) [48,49]. 
The elevated expression of MYOF in the Probasco cell line is suggestive that some EMT is 
present, and that the Probasco cell line may be a suitable model for testing MYOF-based 
therapeutics.
AR signaling is known to be a strong driver of prostate cancer progression in men; however, 
this does not seem to be the case in dogs. The lack of expression of the AR by Probasco is 
consistent with previous data stating that AR is not present in most canine prostate 
carcinomas [12]. Both the lack of AR expression and the frequent development of prostate 
cancer in neutered dogs suggest prostate cancer in dogs rapidly progresses to androgen 
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independence or is derived from cells not maintained by androgen signaling, such as cells of 
the prostatic ducts. It is interesting to note that prostate basal and stem cells are also 
androgen independent and are present in the prostate gland of neutered dogs [6]. 
Investigations into this divergence of pathogenesis of prostate cancer in dogs will be 
valuable in developing novel therapeutics for the disease in dogs.
The genomic determinants for aggressiveness of prostate cancer are still poorly understood. 
Copy number variants in the genome are known to modulate cell function and disease. In 
recent years, several copy number aberrations have been shown to be associated with 
aggressive prostate cancer and poorer prognosis, including deletions in 1p36.13, 3p25, 
3p14.2, 14q32.33, 15p11, and 20p13 and duplications in 12p13, 16q23.3, and 17p13.3 
[50,51]. Array CGH analysis revealed that the Probasco cell line has numerous copy number 
aberrations including deletions in 1p36.13 and duplications in 17p13.3. These findings 
highlights the usefulness of the Probasco cell line as a model of human disease, as even on 
the genomic level there are similarities between the tumors in the two species.
Previous studies of high-resolution aCGH of human prostate specimens revealed numerous 
genome copy number aberrations associated with high-risk disease [52,53]. Among these 
aberrations the most frequent DNA copy number aberrations involve HSA 8, with gains of 
8q (generally involving 8q21.3–24.3 (containing c-MYC) and deletions of 8p (generally 
involving 8p21). Recoded CGH data for Probasco revealed that humanized data did not 
reveal copy number changes in the regions that are evolutionarily conserved with HSA 8p, 
but did reveal complex copy number changes in the region of 8q23–24. The region of HSA 
1 at 1q42.12-q42.3 demonstrated DNA copy gain in a third of human prostate cancers [52]. 
It is interesting to note that not only is this region of the genome also gained in Probasco, but 
that it is flanked by adjacent regions of DNA copy number loss (Fig. 8), perhaps suggestive 
of a region that has retained a critical association with prostate cancer in both species. 
Further consideration of such conserved aberrations, shared between human and dog 
prostate cancers, may provide a means to reduce the regions of significance in the human 
genome as we move toward better refining key genetic pathways and improved treatments.
CONCLUSIONS
Bone metastases are a devastatingly common complication of late state prostate cancer. We 
have developed a canine prostate carcinoma cell line and xenograft model that preferentially 
metastasizes to bone and results in marked new bone formation. This model system will be 
vital in the investigations of the pathogenesis of osteoblastic metastases in prostate cancer.
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Fig. 1. 
Photomicrographs of the primary prostatic carcinoma, the subcutaneous xenograft, and the 
in vitro cell line (Probasco). (A) Photomicrograph of hematoxylin and eosin (H&E)-stained 
primary prostatic carcinoma. The polygonal neoplastic cells form nests and cords separated 
by fibrous connective tissue. (B) Photomicrograph of H&E-stained subcutaneous Probasco 
xenografts. Tumors were multilobular and contained multifocal necrosis and pseudo-cyst 
formation. (C) Phase contrast microscopy of Probasco cells (passage 48).The polygonal 
cells have a tightly packed cobblestone growth pattern.
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Fig. 2. 
In vitro and in vivo growth patterns of Probasco cells. (A) In vitro growth curve of Probasco 
cells. Data presented as mean with a standard deviation of three replicates. (B) Graph 
represents the average bioluminescence measured from subcutaneous xenografts at the 
indicated time points. Data presented as a mean with a standard deviation of 5 mice. (C) 
Graph represents the average tumor volume of the subcutaneous xenografts. Data presented 
as a mean with a standard deviation of 5 mice.
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Fig. 3. 
Expression of select genes in the Probasco prostate cancer cells. (A) Graph represents the 
relative mRNA expression of PTHrP, CXCLI2, SLUG, BMP2, RUNX2, SMAD5, FOLHI, 
MYOF, and CDHI in the Probasco cell line. (B) Graph represents the relative mRNA 
expression of the same genes and the androgen receptor (AR) compared to another canine 
prostate carcinoma cell line, Ace-1 (Student’s t-test; *P<0.05).
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Fig. 4. 
µCT and radiographic analysis of a nude mouse tibia injected with Probasco cells. (A) µCT 
of Probasco injected tibia and control tibia at 3 weeks. Tibias in the Probasco-injected group 
had increased radio-opacity in the diaphyseal region compared to the control bones. (B) 
Radiograph of a control, early (3 weeks) and late (6 weeks) Probasco-injected tibia. The 
early radiographs show increased diaphyseal intramedullary radio-opacity, while the 
radiograph taken at 6 weeks demonstrate the marked periosteal reaction that occurs as 
neoplastic cells exit through the cortex.
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Fig. 5. 
Photomicrograph of H&E-stained tibia 6 weeks post-injection with Probasco cells. 
Neoplastic cells and osteoblasts line new woven bone present within the medullary cavity of 
the diaphysis and along the endosteal surfaces.
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Fig. 6. 
Hybridization of canine autosomal centromeric BAC clones to an example metaphase spread 
of Probasco. In this exam pie the chromosome number was 108. The chromosomes are 
shown with DAPI counterstain (A) and after application of a linear DAPI filter to reveal 
chromosome bands (B). In both cases the Spectrum Green labeled BAC probe reveals the 
presence and location of the centromeres. In this example there are 86 single-armed and 22 
bi-armed structures. The asterisk in A and B indicate two clearly bi-armed chromosomes 
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that did not exhibit autosomal centromere hybridization. This suggests that these two 
structures had sex chromosome-derived centromeres.
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Fig. 7. 
DNA copy number profiling of Probasco. (A) Whole genome copy number profile: X-axis 
shows the 180,000 probes on the CGH array as log2 ratio organized according to 
chromosomal order from the top of CFA I to bottom of the X chromosome. The Y 
chromosome is not represented since the canfam2 genome assembly is female. The y-axis 
shows the log2 ratio of the fluorescence intensity of Cy3-labeled Probasco DNA and Cy5 -
labeled “reference” DNA (y-axis). (B) 460 band ideogram representation of the dog [19] 
with the FASST2 called aberrations from A indicated as copy number gain and loss by 
shading in blue and red, respectively. The data indicate the presence of numerous DNA copy 
aberrations involving gains and losses of small to large, contiguous regions of the canine 
genome as well a complex series of alternating copy number status of CFA13.
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Fig. 8. 
DNA copy number profiling of Probasco recoded to human genome coordinates and output 
as a human data (A) Recoded whole genome copy number data of Probasco as a pseudo-
human profile, with the X-axis shows the 180,000 probes on the CGH array as log2 ratio 
organized according to chromosomal order from the top of human chromosome (HSA) I to 
the bottom of the HSA X. The y-axis shows the log2 ratio of the fluorescence intensity of 
Cy3-labeled Probasco DNA and Cy5-labeled “reference” DNA (y-axis). (B) Human850 
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band ideogram representation of the data in A with the FASST2 called aberrations indicated 
as copy number gain and loss by shading in blue and red, respectively.
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TABLE I
Antibodies Used for Immunohistochemistry of Probasco Cells
Antibody Species Clone Company Dilution
CK AE1/AE3 Mouse M3515 Dako Corporation, Carpinteria, CA 1:100
CK5/6 Mouse D5/16 B4 Dako Corporation, Carpinteria, CA 1:50
CK7 Mouse OV-TL 12/30 Dako Corporation, Carpinteria, CA 1:150
CK20 Mouse Ks20.8 Dako Corporation, Carpinteria, CA 1:250
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TABLE II
Primers Used for qRT-PCR and PCR of Probasco Cells
Gene Forward primer (5′-3′) Reverse primer (5′-3′)
qRT-PCR primers
  BMP2 TGCGCAGCTTCCACCACGAAGAA CAAAGGTTCCTGCATCTGTTCCCGA
  CDH1 GCTGCTGACCTGCAAGGCGA GGCCGGGGTATCGGGGACAT
  CXCL12 ACTGTGCCCTTCAGATCGTGGCA CCACCTGCGCCTCTCACATCTTG
  FOLH1 GCAGGGGACCCTCTCACACCTG CTCGGAAGACCAACAGCCTCTGTGA
  GAPDH CCCACTCTTCCACCTTCGAC AGCCAAATTCATTGTCATACCAGG
  MYOF TGCCCCCGAAAGGCTGGGAAT ACTCCGTGTGCCCTGCGTCT
  RUNX2 TGCCTCTGGCCTTCCACTCTCAG TGCATTCGTGGGTTGGAGAAGCG
  SLUG GGCAAGGCGTTTTCCAGACCCT GGGCAAGAAAAAGGCTTCTCCCCAG
  SMAD5 CCCAGCCAATGGATACAAGC ATGCATGAAAAGCCTCCCCA
  PTHrP AGCTCGGCCGCCGGCTCAA GGAAGAATCGTCGCCGTAAG
  AR CACTCGGCCACCTCAGGGATTGG AACATGGTCCCTGGCAGTCTCCA
PCR primers
  AR Exon 1–1 CCTTTCCAGGAGCTTCCCGCTG CAGCGGAGCGCAAGGACGTA
  AR Exon 1–2 GACAGCGCCAAGGAGTTGTGTAAGG GACAGCGCCAAGGAGTTGTGTAAGG
  AR Exon 2 TAGCCCATGAGAGTGGCTGGTTCC AGGACTGCCCCAGGCTCTAAGC
  AR Exon 3 TGGCCATTCTCTGTTCACTTCTGTC AGCTGGGTGATGGCCACATAGGA
  AR Exon 4 GCTTAGGCAACCTTTCTCACAGGG AGTGGGCATTATACCAATCCCTCCC
  AR Exon 5 TGCTCCTCAGCATTAATGGCCCCT CCAATCCCCCATTGCTTCCCACC
  AR Exon 6 GAGGGCACAGGGACCTGGAAATTC AGGAGCTGGCTTCTCCCCGAT
  AR Exon 7 TGACTGAAGGACCCAGGCGTACA CACCACCCAACAAGAGGTGCCA
  AR Exon 8 TGCATGCGCAAACACAAACACGT TCCCCAAGGCACTGCAGAGTAGT
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